Taxane resistance in metastatic breast cancer and novel microtubuletargeting agents

Abstract

Huang Yuan, Liu Danli, Wang Xiaojia. Taxane resistance in metastatic breast cancer and novel microtubuletargeting agents[J]. Journal of International Oncology, 2016, 43(8): 622-624.

［1］ Barbuti AM, Chen ZS. Paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy［J］. Cancers (Basel), 2015, 7(4): 2360-2371. DOI: 10.3390/cancers7040897. ［2］吴静, 杨睿, 刘树业. 肿瘤多药耐药的产生机制及逆转策略［J］. 国际肿瘤学杂志, 2013, 40(12): 889-892. DOI: 10.3760/cma.j.issn.1673-422X.2013.12.003. ［3］ Karki R, Mariani M, Andreoli M, et al. βⅢTubulin: biomarker of taxane resistance or drug target?［J］. Expert Opin Ther Targets, 2013, 17(4): 461-472. ［4］ Kavallaris M. Microtubules and resistance to tubulinbinding agents［J］. Nat Rev Cancer, 2010, 10(3): 194-204. DOI: 10.1038/nrc2803. ［5］ Rohena CC, Mooberry SL. Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities［J］. Nat Prod Rep, 2014, 31(3): 335-355. DOI: 10.1039/c3np70092e. ［6］ Nobili S, Landini I, Mazzei T, et al. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression［J］. Med Res Rev, 2012, 32(6): 1220-1262. DOI: 10.1002/med.20239. ［7］ Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone［J］. Cancer Chemother Pharmacol, 2009, 63(2): 201-212. DOI: 10.1007/s00280-008-0727-5. ［8］ Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase Ⅱ study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine［J］. J Clin Oncol, 2007, 25(23): 3407-3414. DOI: 10.1200/JCO.2006.09.3849. ［9］ Thomas E, Tabernero J, Fornier M, et al. Phase Ⅱ clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxaneresistant metastatic breast cancer［J］. J Clin Oncol, 2007, 25(23): 3399-3406. DOI: 10.1200/JCO.2006.08.9102. ［10］ Hortobagyi GN, Gomez HL, Li RK, et al. Analysis of overall survival from a phase Ⅲ study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes［J］. Breast Cancer Res Treat, 2010, 122(2): 409-418. DOI: 10.1007/s10549-010-0901-4. ［11］ Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase Ⅲ trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane［J］. J Clin Oncol, 2010, 28(20): 3256-3263. DOI: 10.1200/JCO.2009.24.4244. ［12］ Roché H, Conte P, Perez EA, et al. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase Ⅲstudies［J］. Breast Cancer Res Treat, 2011, 125(3): 755-765. DOI: 10.1007/s10549-010-1251-y. ［13］ Yardley DA. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents［J］. Clin Breast Cancer, 2010, 10(1): 64-73. DOI: 10.3816/CBC.2010.n.009. ［14］ Chuang E, Wiener N, Christos P, et al. Phase Ⅰtrial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary［J］. Ann Oncol, 2010, 21(10): 2075-2080. ［15］ Moulder S, Li H, Wang M, et al. A phaseⅡ trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2positive metastatic breast cancer: an eastern cooperative oncology group trial［J］. Breast Cancer Res Treat, 2010, 119(3): 663-671. DOI: 10.1007/s10549-009-0658-9. ［16］ Vahdat LT, Pruitt B, Fabian CJ, et al. Phase Ⅱ study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane［J］. J Clin Oncol, 2009, 27(18): 2954-2961. DOI: 10.1200/JCO.2008.17.7618. ［17］ Cortes J, Vahdat L, Blum JL, et al. Phase Ⅱstudy of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine［J］. J Clin Oncol, 2010, 28(25): 3922-3928. DOI: 10.1200/JCO.2009.25.8467. ［18］ Cortes J, O′shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician′s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study［J］. Lancet, 2011, 377(9769): 914-923. DOI: 10.1016/S0140-6736(11)60070-6. ［19］ Kaufman PA, Awada A, Twelves C, et al. Phase Ⅲ open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane［J］. J Clin Oncol, 2015, 33(6): 594-601. DOI: 10.1200/JCO.2013.52.4892.

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[5]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[6]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[7]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[8]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[9]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[10]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[11]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui.Research progress of Nrf2 in ovarian cancer[J]. Journal of International Oncology, 2023, 50(8): 493-497.
[12]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[13]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[14]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[15]	Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149.

Taxane resistance in metastatic breast cancer and novel microtubuletargeting agents

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments